Fig. 1: High DPYSL5 expression correlates with increased aggressiveness in prostate cancer.

a DPYSL5 is highly expressed in NEPC patient tumors in the Beltran et al. 2016 dataset. b DPYSL5 expression shows a positive correlation with NEPC score, while (c) a negative correlation with AR Score in the Abida et al. 2019 dataset is observed. d High DPYSL5 mRNA expression correlates with shorter disease-free survival in Taylor et al. 2010 prostate cancer dataset. e Intense DPYSL5 staining is observed in treatment-induced NEPC-like patient tissue samples from the Vancouver CRPC-NEPC TMA cohort. To identify tumor areas, H&E slides of retrieved FFPE tissue blocks were reviewed and annotated by pathologists. Tissue cores from donor FFPE blocks (representative of tumor or non-malignant areas, diameter = 1 mm) were assembled in duplicates into a recipient paraffin block with the semi-automated tissue arrayer TMArrayer (Pathology Devices). f DPYSL5 staining intensity score is significantly increased in NEPC patient tissue samples (n = 55) when compared to untreated (n = 37) and CRPC/TURP (n = 43) tissue samples. g Comparison of DPYSL5 expression intensity patient derived tumor samples (patient derived xenographs, PDX). Samples from patient derived adenocarcinoma (PDX-Adenocarcinoma), CRPC (PDX-CRPC) and NEPC tumors (PDX-NEPC) were included in the analysis. In addition to DPYSL5, staining intensities of AR and NE markers NCAM, CGA and SYP were analyzed. h DPYSL5 staining in PDX tumor samples has a significantly high score in NEPC when compared to other prostate cancer tumor types (adenocarcinoma n = 16, CRPC n = 8 and NEPC n = 4).